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A Diagnostic Tool for Simultaneous Identification of Different
Genetic Markers in Glial Tumors
Judith Jeuken,* Sandra Cornelissen,*
Sandra Boots-Sprenger,*† Sabine Gijsen,* and
Pieter Wesseling*
From the Departments of Pathology * and Neurology,† Nijmegen
Centre for Molecular Life Sciences, Radboud University Nijmegen
Medical Centre, Nijmegen, The Netherlands
Genetic aberrations in tumors are predictive for che-
mosensitivity and survival. A test is needed that al-
lows simultaneous detection of multiple changes and
that is widely applicable in a routine diagnostic set-
ting. Multiplex ligation-dependent probe amplifica-
tion (MLPA) allows detection of DNA copy number
changes of up to 45 loci in one relatively simple,
semiquantitative polymerase chain reaction-based
assay. To assess the applicability of MLPA, we per-
formed MLPA analysis to detect relevant genetic
markers in a spectrum of 88 gliomas. The vast major-
ity of these tumors (n  79) were previously charac-
terized by comparative genomic hybridization. With
MLPA kit P088 (78 cases), complete and partial loss of
1p and 19q were reliably identified, even in samples
containing only 50% tumor DNA. Distinct 1p dele-
tions exist with different clinically prognostic conse-
quences, and in contrast to the commonly used diag-
nostic strategies (loss of heterozygosity or fluorescent
in situ hybridization 1p36), P088 allows detection of
such distinct 1p losses. Combining P088 with P105
will further increase the accurate prediction of clini-
cal behavior because this kit identified markers
(EGFR , PTEN , and CDKN2A) of high-grade malig-
nancy in 41 cases analyzed. We conclude that MLPA
is a reliable diagnostic tool for simultaneous iden-
tification of different region-specific genetic aber-
rations of tumors. (J Mol Diagn 2006, 8:433–443; DOI:
10.2353/jmoldx.2006.060012)
The majority of gliomas can be classified as astrocytic
(As) or oligodendroglial tumors (OTs), the latter including
pure oligodendroglial (Os) or mixed oligo-astrocytic
(OAs) tumors. An accurate distinction between OTs and
As is important because of prognostic and therapeutic
implications.1–3 Unfortunately, unequivocal histopatho-
logical criteria are lacking and differences in clinical be-
havior within a specific histopathological group have
been reported (eg, two thirds of the anaplastic Os re-
spond to PCV chemotherapy [procarbazine, lomustine
(CCNU), and vincristine]).1,3,4 Fortunately, loss of 1p and
19q have been identified as diagnostic molecular mark-
ers in gliomas predicting response to chemotherapy and
long survival.1,5–10 Identification of molecular alterations
involved in the malignant progression of gliomas such as
EGFR amplification and PTEN and CDKN2A loss next to
loss of heterozygosity (LOH) 1p36 was reported to pre-
dict a less favorable prognosis and a less durable re-
sponse to chemotherapy.10–15 A combined molecular
diagnostic approach would therefore be of clinical
relevance.
The most commonly applied techniques, LOH,10,16 flu-
orescent in situ hybridization (FISH),17,18 or quantitative
microsatellite analysis,19,20 specifically analyze the chro-
mosomal region 1p36 to identify OTs with a favorable
prognosis and therapy response. The clinical value of
such tests has been clearly proven. However, not all
chemosensitive OTs were identified, and vice versa,
some of the tumors with a loss of 1p36 proved to be
chemoresistant.1,16 Furthermore, it is becoming increas-
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ingly clear that distinct types of 1p deletions (complete
versus partial) exist in (oligodendro)gliomas, some-
times with opposite clinical and biological conse-
quences.21,22 Unfortunately, however, the above-men-
tioned diagnostic strategies do not discriminate
between these distinct types. Until the exact combina-
tion of genes on 1p/19q responsible for the favorable
clinical behavior of these gliomas have been identified,
analysis of multiple regions on 1p and 19q seems
preferable, thereby enabling an even more accurate
identification of these clinically favorable gliomas. Fur-
thermore, it is noteworthy that techniques identifying
copy number changes such as (array) comparative
genomic hybridization (CGH) identified 1p and 19q
gains in gliomas.23–27 These gains could be easily
misinterpreted as loss of heterozygosity using micro-
satellite approach.23–27
Next to analysis of multiple 1p/19q loci, analysis of
additional genes, for example those reported to be in-
volved in malignant progression, will prove to be of ad-
ditional diagnostic value. Unfortunately, with the above-
mentioned techniques only one or a few loci can be
analyzed per experiment. Array CGH or, at a lower res-
olution, conventional CGH provides an overview of copy
number changes through the entire tumor genome.28–30
Because such experiments are rather specialized, they
are not available in most standard molecular biology
laboratories and may therefore be less suitable for a
routine diagnostic setting. Multiplex ligation-dependent
probe amplification (MLPA) is a technique by which up to
45 different sequences can be targeted in a single, semi-
quantitative polymerase chain reaction (PCR)-based ex-
periment (see Figure 1).31 The sequences detected can
be small (60 nucleotides), enabling analysis of frag-
mented DNA. Furthermore, the MLPA reaction is fast,
relatively inexpensive, and easy to perform, and the
equipment needed for MLPA analysis is present in most
molecular biology laboratories.
Two MLPA kits were designed for molecular analysis of
(oligodendro)gliomas, one to detect copy number
changes on 1p and 19q (kit P088; MRC-Holland, Amster-
dam, The Netherlands) and one to detect aberrations of
EGFR, TP53, PTEN, CDKN2A, and ERBB2 (kit P105; MRC-
Holland). To establish the potential of MLPA in a routine
diagnostic setting, we analyzed a spectrum of 88 glial
tumors using P088 (n  78) and P105 (n  41). The vast
majority (79 of 88) of these tumors were previously char-
acterized genetically by conventional CGH.
Materials and Methods
Samples
Eighty-eight specimens obtained from glioma patients
treated in the Department of Neurosurgery of the Rad-
boud University Nijmegen Medical Centre, The Nether-
lands, were selected. The use of brain tumor tissue after
completing histopathological diagnosis for research pur-
poses was approved by the ethics committee of the
Radboud University Nijmegen Medical Centre, and in-
formed consent was given by the patients. Tumors were
classified according to the World Health Organization–
2000 classification32 and included three pilocytic astro-
cytomas (A-I), six low-grade diffuse astrocytomas (A-II),
one anaplastic astrocytoma (A-III), 24 glioblastomas mul-
tiforme (GBM), nine low-grade oligodendrogliomas (O-II),
16 anaplastic oligodendrogliomas (O-III), seven low-
grade oligo-astrocytomas (OA-II), 17 anaplastic oligo-
astrocytomas (OA-III), three low-grade ependymomas
(E-II), and two anaplastic ependymomas (E-III). Most
Table 1. Guidelines for Reliable Detection of Loss of 1p
and 19q Using MLPA Kit P088
● Percentage of tumor cells in tumor sample should be
at least 50%.
● DNA should be of high quality and preferably isolated
by spin columns (eg, using the DNeasy tissue kit);
DNA isolated differently should be purified.
● Frozen tissue is preferable over formalin-fixed, paraffin-
embedded tissue, but the latter can also be used.
● 250 to 450 ng of DNA should be used.
● Agarose gel electrophoresis should be performed as a
quality control step after the PCR is performed (in
insufficient experiments larger DNA fragments are
underrepresented).
● Evaluation of the MLPA DNA control peaks and ligation
peak (included in each MLPA reaction) should be
performed after capillary gel electrophoresis; relative
peak values should be 0.1 for the DNA control peaks
(64, 70, 76, and 82 bp) and 1.0 for the ligation peak
(94 bp) (peak value divided by the average peak value
of all control probes).
● DNAs used as a reference during data processing
should show normal ratios; otherwise, they should be
excluded from the reference pool.
● Threshold to detect losses and gains in tumor samples
should be set at 0.8 and 1.2, respectively.
● Ratios of adjacent probes should be taken into
consideration for the assessment of the presence of
gains or losses.
Figure 1. Schematic outline of the MLPA procedure. During MLPA analysis up to 45 target-specific probes are used in one reaction. A: The unique target-specific
sequences (gray) of the probes are hybridized on single-stranded genomic DNA (hatched) after which the two adjacent parts of the probe are joined through
ligation and PCR amplification is performed with a fluorescently (FAM) labeled primer (indicated by the asterisk). Because identical PCR primers (black) are used
for all probes, there are no primer-specific advantages in this procedure. Each probe has a unique length [attributable to variation in the length of the stuffer
sequence (light gray)], and therefore gel electrophoresis can be used to separate the individual probe fragments. B: Agarose gel electrophoresis is performed as
an early (and extra) control step for identification of suboptimal MLPA reactions (P088 is shown as an example). DNA fragments are smaller than 500 bp. In
suboptimal samples (; lanes 1 to 3) the large DNA fragments are underrepresented compared to adequate experiments (; lanes 4 to 6). C: Capillary
electrophoresis is performed to identify and quantify the amplification products. Probe names are provided for those located on 1p and 19q. The MLPA mix
includes an internal control for DNA quantity and quality. If these are insufficient, fragments of 64, 70, 76, and 82 bp will appear (indicated by an exclamation
mark in C) whereas a band of 94 bp indicates successful ligation and hybridization (indicated by an L in C). A nonspecific broad peak can be present, with the
size depending on the electrophoresis apparatus and fluorescence used (indicated by an asterisk in C). In this example, MLPA analysis with kit P088 of an
oligodendroglial tumor (N293) with 1p/19q (as detected by CGH) is shown. Subsequently, ratio analysis is performed, and results are visualized showing the
probes in their chromosomal order (described in Materials and Methods; threshold used for losses and gains set at 0.8 and 1.2, respectively).
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samples used in this study (79 of 88) were previously
analyzed by conventional CGH.25–27
DNA was isolated from snap-frozen tumor tissue with
the DNeasy tissue kit, as described by the manufacturer
(Qiagen, Venlo, The Netherlands), supplemented with an
additional wash step using the supplied wash buffer AW2
before elution. In case of paraffin-embedded tissue,
50-m paraffin sections were cut and incubated in P-
buffer (50 mmol/L Tris-HCl, pH 8.2, 100 mmol/L NaCl, 1
mmol/L ethylenediaminetetraacetic acid, 0.5% Tween 20,
0.5% Nonidet P-40, 20 mmol/L dithiothreitol) at 90°C for
15 minutes, after which a protein digestion was per-
formed using 0.5 mg/ml of proteinase K (Roche Diagnos-
tics GmbH, Mannheim, Germany) at 55°C overnight. Sub-
sequently, DNA was isolated using the DNeasy tissue kit.
Furthermore, DNA previously isolated using a salting out
procedure25,33 was purified using the DNeasy tissue kit.
MLPA Procedure
P088 contains 15 1p probes, eight 19q probes, and 21
control probes specific to other chromosomes (MRC Hol-
land). During our study a minor change (replacement of
two 1p probe by a new 1p and control probe) was intro-
duced by the manufacturer, and lot-nr 0804 was re-
placed by lot-nr 0305. SALSA P105 (lot-nr 0804) contains
nine PTEN probes, five CDKN2A probes, eight TP53
probes, three EGFR probes, two ERBB2 probes, and 15
control probes. All MLPA probe pairs code for unique
human single copy DNA sequences and were designed
and prepared as described by Schouten and col-
leagues.31 Probe sequences and genes detected by the
control probes are available on request by the manufac-
turer (MRC Holland). Probes used to detect imbalances
are listed in Figures 2 to 5.
MLPA was performed as described by the manufac-
turer with minor modifications. Briefly, DNA (250 to 450
ng) was dissolved in 5 l of TE-buffer (10 mmol/L Tris, pH
8.2, 1 mmol/L ethylenediaminetetraacetic acid, pH 8.0) or
Milli-Q water, denatured, and subsequently cooled to
25°C. After adding the probe mix, the sample was dena-
tured, and the probes were allowed to hybridize (16
hours at 60°C). After ligation of both probe pairs and
inactivation of ligase, PCR was performed in a volume of
50 l containing 10 l of the ligation reaction mixture
using the PTC 200 thermal cycler (MJ Research Inc.,
Waltham, MA) (33 cycles of denaturation at 95°C for 20
seconds, annealing at 60°C for 30 seconds, and exten-
sion at 72°C for 1 minute with a final extension of 20
minutes at 72°C). We included an additional agarose gel
electrophoresis to examine MLPA efficiency (Figure 1).
Fragments were separated and quantified by electro-
phoresis on an ABI 3730 capillary sequencer (Applied
Biosystems, Foster City, CA) and Genemapper analysis
(Applied Biosystems).34
In each set of MLPA experiments, in addition to the
tumor samples to be analyzed, we included at least four
normal control DNA samples for data processing. Refer-
ence DNAs were isolated either from blood of healthy
volunteers or from normal (nontumorous) paraffin-em-
bedded samples for use in MLPA analysis of tumor DNAs
from frozen or paraffin-embedded tissue, respectively.34
MLPA Data Processing
Data analysis was performed in Excel as described by
the manufacturer (MRC-Holland). First, the fraction of
each peak was calculated by dividing the peak value
(peak height or area) of each probe amplification product
by the combined value of the control probes within the
sample, to compensate for PCR efficiency of the individ-
ual samples. Subsequently this relative peak value or
so-called probe fraction is divided by the mean probe
fraction of this fragment within the included reference
DNAs, generating the normalized peak value or the so-
called probe ratio.
For quality control, five control peaks were included in
each reaction: four control fragments generating amplifi-
cation products of 64, 70, 76, and 82 bp if the DNA
quality (amount or purity) is insufficient, and a fifth peak
showing an amplification product of 94 bp that is indica-
tive for hybridization and ligation efficiency. For these
quality control fragments, the relative peak values are
calculated (peak value/average peak value of the control
probes within a sample) to identify unreliable experi-
ments (Table 1). Based on our previous experience with
MLPA kit P00534 and the current data set described in
this study, the threshold was set at 0.8 for identification of
losses and at 1.2 for gains. Ratios of the control probes
were not further analyzed because these probes were
targeting dispersed regions of different chromosomes,
and for reliable detection of aberrations by MLPA, multi-
ple probes for the gene or region of interest need to be
analyzed.34
Results
Detection of 1p/19q
MLPA experiments were performed using 250 to 450 ng
(depending on concentration and availability) of control
and tumor DNA isolated from snap-frozen tissue or for-
malin-fixed, paraffin-embedded tissue. Overall, tumors
Figure 2. Overview of the results of MLPA analysis of gliomas using kit P088 for detection of losses on chromosome 1p and 19q. In the top row the probe names
analyzed are listed in chromosomal order. Red boxes represent ratios surpassing the threshold set to detect a loss (0.8), whereas green boxes show a ratio greater
than 1.2. White boxes without a ratio are present as during our study 2 probes in kit P088 were replaced by others (EPHA8 and RUNX3 were only present in lot
0408). The left column contains tumor identification numbers (-f and -p: tumor DNA from snap-frozen or paraffin-embedded tissue, respectively). Tumors are
grouped based on the CGH results, containing a complete loss of 1p and 19q, no losses or gains on 1p or 19q, or gains involving 1p and 19q, respectively. Tumors
containing partial deletions are shown in Figure 4. In the next column the histopathological diagnosis is given (for abbreviations see Materials and Methods)
followed by columns with the results of previous CGH analysis with regard to chromosome 1p and 19q (n, no aberration detected; , loss of chromosome arm;
, gain of chromosome arm; nd, not done; (), CGH ratio clearly deviating from the normal ratio but not crossing the threshold that was set to detect a loss (0.8)
or gain (1.2) by CGH).
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showing loss of the complete chromosome arm 1p and/or
19q as detected by CGH also showed loss of nearly all
1p and/or 19q probes (Figure 2). Vice versa, only occa-
sional probes showed a loss in tumors without loss in-
volving 1p or 19q as identified by CGH analysis. Figure 3
shows an overview of mean probe values  2	 standard
deviations in the control DNAs used in combination with
the individual ratios for tumors with a complete loss of
1p/19q as detected by CGH. Partial deletions as de-
tected by CGH were also detected by MLPA and could
be better mapped with this latter technique (Figure 4).
Although a loss is identified by a ratio less than 0.8, ratios
greater than 1.2 indicate gained regions. Although CGH
only detected a gain in a small number of cases (Figure
2), probes showing a ratio 1.2 were relatively frequently
identified (as an isolated event or involving adjacent
probes). So far the diagnostic value of 1p/19q imbal-
ances encompasses detection of losses, and further
evaluation of gains was considered beyond the scope of
the present study.
Quality Control
To test the amount of normal DNA that can be present
in a DNA-tumor sample without affecting MLPA reliabil-
ity, a titration experiment was performed using DNA
isolated from a subcutaneous human glioma xenograft
line (E34) containing loss of 1p and 19q.35 As ex-
pected, MLPA probe ratios increased with increasing
amounts of normal DNA (0, 20, 40, 50, 60, 80, and
100%) (data not shown). We found that loss of 1p and
19q can still reliably be detected in a sample contain-
ing 50% tumor DNA. The theoretically expected ratios
for a loss of 0.5 (one of two alleles lost) were indeed
detected in the 100% tumor DNA sample whereas in
the sample with only 50% tumor cells, derived DNA-
detected ratios were 0.75 (ie, the theoretical ex-
pected value).
Evaluating the MLPA quality control fragments in the
P088 kit in our hands reliably showed relative peak values
(peak value/average peak value of all control probes
within the sample) of less than 0.1 for the DNA control
peaks (64, 70, 76, and 82 bp), whereas the relative
ligation peak (94 bp) value was at least 1, but usually
greater than 1.2. An additional quality control step using
agarose gel electrophoresis before capillary electro-
phoresis enabled us to reliably identify experiments that,
after data processing, appeared to provide unreliable
detection of 1p and 19q. In such inefficient ex-
periments, agarose gel electrophoresis demonstrated
under-representation of larger DNA fragments (see also
Figure 1B).
Duplicate experiments were performed on 13 tumor
DNAs, and probe ratios showed only minor differ-
Figure 3. Overview of the distribution of individual probe ratios in control and 1p/19q-containing samples. The x axis shows probe names in chromosomal
order whereas the y axis shows ratios. Probe ratios for the reference DNAs are shown in gray, and ratios in tumors with a complete loss of 1p and 19q as detected
by CGH are shown in black. For reference DNA, horizontal lines represent mean probe values; vertical lines represent mean values  2 times SD; dot represents
individual probe ratio. The increased variation in probe ratios among the1p/19q tumors compared to the control samples is caused by the fact that the amount
of tumor cells within a tumor sample directly affecting the probe ratios varies among the different tumors. Mean probe ratios and standard deviations were
therefore not calculated for tumor DNA.
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ences. Furthermore, of 11 cases (6 without a loss on 1p
or 19q as detected by CGH) analyzed using DNA
isolated from paraffin-embedded tissue (p-DNA),
MLPA was repeated using DNA isolated from frozen
tissue (f-DNA) because several probes showed unex-
pected ratios in comparison to the CGH analysis or
adjacent probes. In nine of these cases, the results
improved using f-DNA; however, the same conclusions
could be drawn from both the f-DNA and p-DNA anal-
ysis. In the remaining two cases, the results for f-DNA
were similar to those obtained with p-DNA. Based on
our experience guidelines were established for reliable
detection of (partial or complete) losses on chromo-
some arms 1p and 19q in tumors (Table 1).
Detection of Other Genetic Markers
With MLPA kit P105 (testing EGFR, CDKN2A, PTEN, TP53,
and ERBB2, located on 7p12, 9p21, 10q23.3, 17p13.1,
and 17q21.1, respectively), we investigated 41 gliomas
(Figure 5). Aberrant probe ratios for EGFR, CDKN2A, and
PTEN were detected in the majority of the cases in which
CGH identified an imbalance of the corresponding region
(11 of 13, 10 of 12, and 16 of 17 cases, respectively).
Furthermore, several aberrations were detected by MLPA
that were not identified by CGH; this is most likely a result
of the detection limit of CGH (2 to 10 Mb). Interestingly, all
seven cases that contained high copy amplification of the
7p12 region as identified by CGH were also identified as
Figure 4. Overview of the detection of partial 1p and 19q losses using MLPA kit P088. A: Partial deletions as detected by MLPA kit P088. Legends are as described
for Figure 2. Partial deletions as detected by CGH are listed on the left. Red and green boxes represent probe ratios 0.8 and 1.2. Additionally, yellow and light
green boxes represent regions that, based on the relative low/high ratios and ratios of adjacent probes, were considered to be lost or gained even though the
threshold (0.8 and 1.2) was not reached. The total deleted or gained regions as detected by this method are boxed in black. B: An example of comparison of
conventional CGH analysis (left) and MLPA analysis using kit P088 (right) both identifying a partial deletion on 1p and 19q (case N182). The partial deletions
detected in case N182 by CGH involve 1p11-31 and 19q13.2-qter, whereas MLPA detects a loss on 1p from NRAS (1p13.1) to LPHN2 (1p31.1) and a loss on 19q
from ZNF342 (19q13.32) to BC2 (19q13.43); in addition, MLPA analysis shows a partial gain on 19q, and this gain is also indicated by CGH, but here the threshold
is not crossed.
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such by MLPA, with the EGFR ratios primarily surpassing
the 1.2 threshold (ranging from 3.6 to 26.5). Ratios for the
CDKN2A probes ranged from 0.06 to 0.10 in N255, sug-
gesting a homozygous deletion in the majority of the cells
analyzed. Only in one case (N124) was an imbalance
involving 17p13.1 clearly detected by CGH, demonstrat-
ing the need for evaluation of the reliability of these TP53
probes using gene-specific information. Furthermore,
both probes included in P105 to analyze ERBB2 fre-
quently showed opposite results, and it remains unclear
which one is reliable. This finding underscores our pre-
vious observations that three or more probes should be
analyzed for reliable detection of imbalances in the gene
or chromosomal region of interest.34 Overall, aberrations
previously identified by CGH, including the EGFR,
CDKN2A, and PTEN region (7p12, 9p21, and 10q23,
respectively), were correctly identified by P105 in the
majority of cases.
Combining the P105 and P088 data of the 31 tumors
that were analyzed with both kits, we found that a gain of
EGFR usually does not coincide with 1p/19q. Dele-
tions of the CDKN2A gene were present in approximately
one third of the tumors, irrespectively of their 1p/19q
status. PTEN deletions were detected at a somewhat
higher frequency in tumors without a 1p/19q loss
[72% (18 of 25) versus 57% (8 of 14) of the cases,
respectively].
Discussion
An increasing number of molecular markers with prog-
nostic value in predicting better survival or response to
therapy have been identified for different tumor types.
Implementation in a routine diagnostic setting is war-
ranted, preferably using techniques that enable simulta-
neous detection of multiple markers or loci and are not
dependent on highly specialized equipment or person-
nel. MLPA is a very promising technique for routine diag-
nostics because it allows detection of DNA or RNA copy
number changes of up to 45 loci in one relatively simple,
semiquantitative PCR-based experiment.31 Most MLPA
kits available are designed for oncological purposes and
address either hereditary or sporadic tumors. Germline
aberrations are easily detected, but analysis of (spo-
radic) tumor samples is much more complex because a
whole spectrum of different chromosomes can be af-
fected. Therefore, the included control probes need to be
Figure 5. Results of MLPA analysis of gliomas using kit P105 (for EGFR, CDKN2A, PTEN, TP53, and ERBB2). See also legend in Figure 2. The probe names (gene
name and exon analyzed are indicated) are listed; probe CDKN2A prom is located in the promotor region, CDKN2A intA is located 0.5 kb before the start of
p14ARF exon 1, CDKN2A intB is located between p16 exon 1 and p14 exon 1, whereas ERBB2 1 and ERBB2 2 represent the 142-bp and 409-bp fragment of ERBB2
2, respectively (exact location not provided). CGH results are provided for chromosomal regions on which the genes are located [7p12 (EGFR), 9p21 (CDKN2A),
10q23.3 (PTEN), 17p13.1 (TP53) and 17q21.1 (ERBB2)]. Abbreviations used for CGH imbalances are as in Figure 2; the following symbols are also used: , CGH
ratio of 0.6 suggesting the presence of a homozygous deletion, , high copy amplification as indicated by a CGH ratio greater than 1.4. Red and green boxes
represent probe ratios less than 0.8 and more than 1.2. Additionally, dark green boxes represent MLPA ratios more than 2.0 indicating high copy number
amplifications, whereas pink boxes represent ratios less than 0.4, which may indicate homozygous deletions.
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carefully selected and located on different chromosomes
that are infrequently affected in the tumor type of interest.
Furthermore, aberrations are usually only present in a
subpopulation of the cells analyzed because of tumor
heterogeneity or contaminating DNA from normal cells in
the tumor tissue. Less stringent thresholds are therefore
required to enable detection of such aberrations. Two
recently designed MLPA kits are of special interest for
glial tumors: one to identify loss of 1p and 19q (P088),
which are indicative for chemosensitivity and long sur-
vival, and another to detect amplification or loss of EGFR,
CDKN2A, and PTEN (indicating malignant progression)
as well as amplification or loss of TP53 and ERBB2
(P105). In the present study we evaluated these kits using
genetically characterized gliomas to establish the poten-
tial of MLPA in a routine diagnostic setting.
Detection of 1p/19q
Early in 2003 the first MLPA kit was released that was
specifically designed for detection of loss of 1p and 19q.
In our pilot study we analyzed 14 (oligodendro)glial tu-
mors with (n  8) or without (n  6) losses on 1p/19q as
identified by CGH (unpublished data). Because we no-
ticed that the design of this original kit was suboptimal,
suggestions for improvement were provided to the man-
ufacturer.36 Recently, a study was published by Natte´
and colleagues37 describing the use of this original kit on
19 tumors. An adapted way of data processing was
proposed, analyzing only the 22 reliable probes (22 of
40) but enabling identification of their 1p/19q gliomas
as established by FISH. Tumors were considered to have
a loss when at least four of the seven 1p probes or two of
the four 19q probes showed a ratio less than 0.75. Fol-
lowing the procedure proposed by Natte´ and col-
leagues,37 we could indeed classify the seven tumors in
our pilot study showing a complete 1p loss and five of the
six tumors without this loss. However, a tumor containing
a partial deletion of 1p11-31 was classified as a tumor
without 1p loss. Identification of complete versus partial
losses of 1p/19q in a single and relatively simple exper-
iment is one of the advantages of MLPA over LOH or FISH
and might prove to be of additional diagnostic value.
Using this original kit the potential of MLPA is thus not
fully exploited. A new kit has been designed for the
detection of losses on 1p and 19q and is now commer-
cially available (P088).
In the present study we show that, using this improved
MLPA kit (P088), complete as well as partial losses of 1p
and 19q can easily be identified. Vice versa, tumors
without these losses at the CGH level were classified as
such. Tumors not previously characterized by CGH could
also easily be classified as having complete loss of 1p
and 19q (N471 and N355) or as tumors without such
losses (N181, N372, N399, and N400). Only in one case
(N256) the MLPA results were difficult to interpret be-
cause in this tumor dispersed, nonadjacent 1p probes
showed a ratio 0.8. Because pre-existent brain tissue
was reported to be present in this case, MLPA analysis
for diagnostic purposes using a tissue sample with a
higher tumor load is warranted to provide more accurate
results.
In cases without a clear complete loss of 1p or 19q, but
with several adjacent probes on (one of) these chromo-
some arms showing a ratio 0.8, true partial deletions
are likely to be present. Indeed, in some of these cases
CGH ratios of 0.9 were detected (0.8 also being the
threshold to detect losses at the CGH level) for the cor-
responding region. The scattered loss of individual 1p or
19q probes in tumors in which CGH did not detect a
(partial) loss may represent small deletions that are un-
detectable by CGH. Alternatively, scattered losses for
only part of the 1p or 19q probes may occur when these
aberrations are present in a subpopulation of the cells. In
several cases, ratios greater than 1.2 were detected for
1p and 19q probes while CGH did not indicate a gain.
Because a ratio 1.2 often occurred in adjacent probes,
this likely represents a partial gain that is too small to be
detected by CGH. Furthermore, although this kit was
designed to detect losses on 1p and 19q, probes for two
genes on 19p (19p13.3; LDLR and SMARCA4) are in-
cluded to distinguish losses restricted to 19q from loss of
the complete chromosome 19. In contrast to gains (14
cases), losses of both 19p probes were not detected
(data not shown). If preferred these 19p probe might be
used to calculate relative copy number losses as per-
formed during FISH analysis (19q/19p). However, this
approach might be complex when partial losses are
involved.
Quality Control
Our titration experiment revealed that MLPA analysis for
1p and 19q is rather robust and that a sample con-
taining 50% of tumor cell-derived DNA can still be cor-
rectly identified. However, in our experience DNA used
for MLPA analysis should be of high quality and 250 to
450 ng of DNA per tumor enables reliable identification of
aberrations. Two control steps are instrumental in estab-
lishing the efficiency of MLPA: agarose gel electrophore-
sis after PCR (Figure 1) and subsequent evaluation of the
MLPA quality control peaks after capillary electrophore-
sis (Table 1). Using agarose gel electrophoresis, some
additional inefficient experiments were identified that
were not recognized by evaluation of the quality control
peaks. Furthermore, in some tumors a relative ligation
peak less than 1.0 occurred because of a deletion includ-
ing the ligation-specific control probe sequence (2q14).
This occurred in combination with adequate results for
DNA control peaks ( 0.1) and in this case is therefore
not indicative for an inefficient experiment.
Detection of Other Genetic Markers
Of the tumors included in this part of the study, informa-
tion about chromosomal imbalances (based on previous
CGH investigations) was available for 37 of 41 cases.
Because the P105 kit analyzes specific exons of genes,
using the CGH information for validation of the results
obtained by MLPA kit P105 analysis is less straightfor-
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ward than for the MLPA kit P088, and further validation of
P105 is warranted using gene-specific information for
comparison. Nevertheless, in the majority of CGH and
MLPA tumors analyzed showed comparable results for
the chromosomal regions of EGFR, CDKN2A, PTEN, and
TP53. Moreover, probe ratios enabled identification of
high copy amplifications of EGFR or homozygous dele-
tions of CDKN2A. MLPA detected several aberrations that
were not identified by CGH, probably because of the
detection limit of CGH (ie, 2 to 10 Mb), including a high
copy gain for EGFR in one tumor.
Comparison of the results obtained with P088 and
P105 revealed that differences in ratios between adjacent
probes more often occurred in P105. As in 31 cases the
same DNA stock was analyzed using P105 as well as
P088, these differences are most likely not caused by
DNA quality, quantity, or the presence of nontumorous
cells. Although 1p and 19q are early events in the
oncogenesis of (oligodendro)glial tumors, PTEN, EGFR,
and CDKN2A aberrations are considered to be involved
in malignant progression (late events).38 Such progres-
sion-associated aberrations may only be present in part
of the tumor cells (tumor heterogeneity) and, as dis-
cussed above, may increase the chance of obtaining
inconclusive results. Alternatively, as different regions in
the genes are analyzed, these results may reflect the fact
that some exons are more prone to aberrations than
others.
The data processing for the results obtained with the
P105 kit was performed in the same way as for the P088
kit. An alternative data processing procedure was sug-
gested by the manufacturer [calculating the fractions
using the sum of the nearest (fragments length) two to
four control peaks instead of all control peaks]. However,
this alternative approach did not improve the results.
Because multiple chromosomal aberrations are usually
present in tumors, part of the control probes may target
regions containing an imbalance. Evaluation of too few
control probes for data processing may in this situation
primarily affect the calculation of the ratio of the probes of
interest and lead to unreliable results.
Diagnostic Potential of MLPA Using Kit P088
and P105
The demand for implementation of molecular diagnostics
in glioma patients is increasing. Usually LOH or FISH
methods are used to detect loss of the 1p36 region,
generally identifying a group of OTs with better chemo-
response and (progression-free) survival. In this study we
established the clinical potential of MLPA for glioma di-
agnostics. Rather than evaluating an MLPA kit (P147)
designed to analyze 1p36, we validated MLPA kit P088,
which is designed to detect complete as well as partial
deletion on 1p and 19q because it is becoming increas-
ingly clear that there are distinct types of 1p/19q losses
with specific clinical characteristics. For example, com-
plete 1p loss associated with a complete 19q loss (with-
out 19p loss) predicts longer survival and a better che-
moresponse compared to partial telomeric or interstitial
1p losses not associated with a (complete)19q
loss.8,21,23 In contrast, it has been reported that gliomas
with partial LOH 1p and LOH 19q have a better chemo-
response.22 Concordantly, one of the patients in our se-
ries with an OA harboring 1pcen-p31 and 19q13.2-
qter (Figure 4) showed a long survival (16 years since first
surgery for low-grade glioma, which 9 years later ap-
peared to have progressed to anaplastic OA at the his-
topathological level; unpublished data). Based on our
results we conclude that using MLPA kit P088 reliably
identifies not only complete but also partial losses on 1p
and 19q in gliomas from both snap-frozen and paraffin-
embedded tumor tissue containing at least 50% tumor
cells. Using another MLPA kit (P105), genetic markers
such as EGFR, PTEN, and CDKN2A [indicating high-
grade malignancy in (glial) tumors] can be identified.
Combining data of P088 and P105 thus enables identifi-
cation of those 1p/19q tumors that harbor these ad-
ditional aberrations associated with malignant progres-
sion and reported to be predictive for shorter overall
survival and duration of chemoresponse.10 Conse-
quently, identification of these latter aberrations (P105) in
gliomas without 1p/19q losses will also be predictive for a
less favorable outcome.
Because MLPA is rather robust and relatively easy to
perform, we expect that implementation of this technique
will be very helpful in making genetic information that is
relevant for estimation of prognosis and therapy available
for individual glioma patients and will thereby facilitate
customized therapeutic decision making. Furthermore,
MLPA can be easily used to screen large sets of gliomas
and will therefore enable further evaluation of the thera-
peutic and prognostic implications of complete versus
specific partial 1p/19q losses (P088) as well as the ad-
ditional diagnostic value of a gain of EGFR and loss of
CDKN2A and PTEN in cases with or without 1p/19q
losses (P105).
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